Depemokimab for Severe Eosinophilic Asthma in People With Allergic Bronchopulmonary Aspergillosis
Tests depemokimab in adults with severe eosinophilic asthma and allergic bronchopulmonary aspergillosis.
Plain-language title generated from the registry record
Registry title: Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
Key facts
- Where
- Jinan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07828327, who can take part
Where in China
- Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, ChinaJinan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qianfoshan Hospital
- Trial code
- NCT07828327
- Record updated
- 24 September 2026
- Original description
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosisRead full original descriptionShow less
Effectiveness and Safety of Depemokimab in Allergic Bronchopulmonary Aspergillosis (ABPA) With Severe Eosinophilic Asthma(SEA): a Prospective Study of Real-world Experience
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
Inclusion: Female and Male patients aged 18-75 years; Diagnosis of Allergic Bronchopulmonary Aspergillosis (according to the ISHAM Working Group Diagnostic Criteria); Severe asthma requiring treatment with high dose ICS plus a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control).
Exclusion: Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational; History of allergy or hypersensitivity reaction to Depemokimab or any of its components; Currently pregnant, breastfeeding, or lactating women.